Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

Molecular processes of chromosome 9p21 deletions in human cancers

Abstract

Interstitial deletions of the chromosome 9p21 segment encoding the p16/CDKN2A tumor suppressor gene (i.e., 9p21 deletions) are frequently observed in a variety of human cancers. A majority of these deletions in lymphoid leukemia have been indicated to be mediated by illegitimate V(D)J recombination. In the present study, to elucidate the molecular processes of 9p21 deletions in nonlymphocytic malignancies, breakpoints for these deletions were analysed in 21 lung cancer cell lines and 32 nonlymphocytic cancer cell lines of nine other histological types. In all, 32 breakpoints in 21 lung cancer cell lines and 56 breakpoints in 32 nonlung cancer cell lines were mapped in a 450-kb segment encompassing the CDKN2A locus with a 10-kb resolution. The largest number of breakpoints (i.e., seven breakpoints in lung cancer and 12 breakpoints in nonlung cancers) was mapped in a 10-kb region containing the CDKN2A gene. More precise mapping of these seven and 12 breakpoints revealed that none of these breakpoints were located within 50-bp intervals to each other in this 10 kb region. Cloning and sequencing of breakpoints in 18 representative cell lines (six lung and 12 nonlung cancers) further revealed that there were no significant homologies among breakpoints in these 18 cell lines. In 11 (61%) cell lines, 1–5-bp nucleotides were overlapped at breakpoint junctions. These results indicate that DNA double-strand breaks triggering 9p21 deletions do not occur at specific DNA sequences, although they preferentially occur in or near the CDKN2A locus. It was also indicated that two broken DNA ends are rejoined by nonhomologous end-joining repair, preferentially utilizing microhomologies of DNA ends, in the occurrence of 9p21 deletions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Canning S and Dryja TP . (1989). Proc. Natl. Acad. Sci. USA, 86, 5044–5048.

  • Cayuela JM, Gardie B and Sigaux F . (1997). Blood, 90, 3720–3726.

  • Drexler HG . (1998). Leukemia, 12, 845–859.

  • Hamada K, Kohno T, Kawanishi M, Ohwada S and Yokota J . (1998). Genes Chromosom. Cancer, 22, 232–240.

  • Hamada K, Kohno T, Takahashi M, Yamazaki M, Tashiro H, Sugawara C, Ohwada S, Sekido Y, Minna JD and Yokota J . (2000). Genes Chromosom. Cancer, 27, 308–318.

  • Hoeijmakers JH . (2001). Nature, 411, 366–374.

  • Inoue H, Ishii H, Alder H, Snyder E, Druck T, Huebner K and Croce CM . (1997). Proc. Natl. Acad. Sci. USA, 94, 14584–14549.

  • Jasin M . (2000). Cancer Invest., 18, 78–86.

  • Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE and Skolnick MH . (1994). Science, 264, 436–440.

  • Kitagawa Y, Inoue K, Sasaki S, Hayashi Y, Matsuo Y, Lieber MR, Mizoguchi H, Yokota J and Kohno T . (2002). J. Biol. Chem., 277, 46289–46297.

  • Kohno T, Otsuka T, Inazawa J, Abe T and Yokota J . (1996). DNA Res., 3, 421–424.

  • Lewis SM . (1994). Adv. Immunol., 56, 27–150.

  • Lieber MR . (1999). Genes Cells, 4, 77–85.

  • Mimori K, Druck T, Inoue H, Alder H, Berk L, Mori M, Huebner K and Croce CM . (1999). Proc Natl. Acad. Sci. USA, 96, 7456–7461.

  • Nishioka M, Kohno T, Takahashi M, Niki T, Yamada T, Sone S and Yokota J . (2000). Oncogene, 19, 6251–6260.

  • Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA . (1994). Nature, 368, 753–756.

  • Ochman H, Gerber A S and Hartl DL . (1988). Genetics, 120, 621–623.

  • Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, Yamamori S and Hayashi Y . (1995). Blood, 86, 1269–1275.

  • Park M, Shimizu K, Nakano T, Park YB, Kohno T and Yokota J . (2002). Cancer Genet. Cytogenet., 141, 5–13.

  • Pomykala HM, Bohlander SK, Broeker PL, Olopade OI and Diaz MO . (1994). Mol. Cell. Biol., 14, 7604–7610.

  • Roth DB and Wilson JH . (1986). Mol Cell Biol., 6, 4295–4304.

  • Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Resell R, Monzo M, Wu L, Westra WH, Yang SC, Jen J and Sidransky D . (2001). Cancer Res., 61, 1309–1313.

  • Sekido Y, Ahmadian M, Wistuba II, Latif F, Bader S, Wei MH, Duh FM, Gazdar AF, Lerman MI and Minna JD . (1998). Oncogene, 16, 3151–3157.

  • Sherr CJ . (2000). Cancer Res., 60, 3689–3695.

  • Smerdon MJ and Conconi A . (1999). Prog. Nucleic Acid Res. Mol. Biol., 62, 227–255.

  • Smith J, Baldeyron C, De Oliveira I, Sala-Trepat M and Papadopoulo D . (2001). Nucleic. Acids Res., 29, 4783–4792.

  • Tanaka H, Shimada Y, Imamura M, Shibagaki I and Ishizaki K . (1997). Int. J. Cancer, 70, 437–442.

  • Tremblay A, Jasin M and Chartrand P . (2000). Mol. Cell. Biol., 20, 54–60.

  • Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, Samet JM, Srivastava S, Minna JD and Gazdar AF . (1997). J. Natl. Cancer Inst., 89, 1366–1373.

Download references

Acknowledgements

This study was supported in part by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan for Scientific Research on Priority Areas (KAKENHI 14026064), the Program for Promotion of Fundamental Studies in Health Sciences of the Organization for Pharmaceutical Safety and Research of Japan, the Ministry of Health, Labour and Welfare of Japan for the 2nd-term Comprehensive 10-Year Strategy for Cancer Control, and National Cancer Institute Specialized Programs of Research Excellence Grant P50 CA70907, and the Foundation for Promotion of Cancer Research. We thank the following scientists for providing us cell lines: Drs WK Cavenee, IJ Fidler, AF Gazdar, Y Hayata, S Naito, M Oshimura, T Sekine, Y Shimada, M Takada, M Terada, N de Tribolet and M Yoshida. Cell lines were also obtained from the American Type Culture Collection, the Japan Cell Resource Bank and the Institute for Fermentation, Osaka, Japan. We also thank Ms M Takahashi for technical assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jun Yokota.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sasaki, S., Kitagawa, Y., Sekido, Y. et al. Molecular processes of chromosome 9p21 deletions in human cancers. Oncogene 22, 3792–3798 (2003). https://doi.org/10.1038/sj.onc.1206589

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206589

Keywords

This article is cited by

Search

Quick links